Semaglutide vs. tirzepatide: what actually differs between them

Semaglutide and tirzepatide get discussed together so often that it's easy to assume they're interchangeable — two brand names, or two compounding options, for essentially the same drug. They aren't. Both are once-weekly injectable GLP-1 medications, but they work on a different number of hormone receptors, and that mechanical difference is the actual starting point for understanding how they differ.

Semaglutide activates one receptor: GLP-1, a hormone your gut releases after eating that signals the pancreas, slows digestion, and reduces appetite. Tirzepatide activates two: the same GLP-1 receptor, plus a second receptor for a hormone called GIP. That's why tirzepatide is described as a "dual agonist" and semaglutide is not — it's a description of which receptors the molecule binds to, not a claim about how much weight either one helps a given person lose.

That second pathway is also why the two medications aren't simply interchangeable at the prescription level. A clinician deciding between them is weighing a different receptor-binding profile, not choosing a stronger or weaker version of the same drug — which is also why switching from one to the other, if it's ever appropriate, is a decision for a prescribing clinician to make with a specific patient rather than something to decide from a comparison article.

How each one is dosed

Both medications are prescribed on a titration schedule — a low starting dose that increases at intervals, typically every few weeks, rather than a single fixed dose from day one. The exact schedule differs by medication and by the specific product a patient is prescribed, so a titration calendar for one does not transfer directly to the other; the specifics come from the prescribing clinician and the label for whichever product is actually dispensed.

Side effects, compared honestly

The two medications share a broadly similar side-effect profile, because both slow gastric emptying as part of how they work: nausea, vomiting, diarrhea, constipation, and fatigue are reported with either one, particularly early in treatment or after a dose increase. Neither one is free of this class-wide effect, and neither is reliably milder than the other in a way this article can state as fact — that question is exactly the kind a qualified clinician is positioned to discuss, because individual response varies more than a general comparison can capture.

What each one costs here

Cost is one of the few differences that can be stated as a plain fact rather than a clinical judgment. On Leland, semaglutide is priced at $129 per 4 weeks and tirzepatide at $219 per 4 weeks. Each is a starting price, billed every 4 weeks. On Leland, tirzepatide currently costs more than semaglutide as an injectable plan; that difference is not a reflection of which one is more appropriate for anyone specifically.

How the decision actually gets made

Deciding between the two is a clinical conversation, not a comparison-shopping decision: a prescribing clinician weighs a patient's medical history, any prior GLP-1 experience, other medications, and individual response to figure out which option — if either — is appropriate. This article can describe what differs between the molecules; it can't tell a specific reader which one to take, and doesn't try to.

Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. That's true of either medication discussed here, regardless of which one a patient and their clinician land on.

Nothing here is medical advice, and nothing recommends one medication over the other for any particular person. A qualified clinician, working from a full medical history, determines whether either medication — or neither — is appropriate for you.